{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:59:19Z","timestamp":1772135959249,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Beijing Bethune Charitable Foundation","award":["2018-Z-08"],"award-info":[{"award-number":["2018-Z-08"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Intravitreal anti-vascular endothelial growth factor (VEGF) agents have revolutionized the treatment of retinopathy of prematurity (ROP); however, there are concerns regarding the potential systemic complications caused by those treatments. This study aimed to determine the serum concentrations of cytokines in infants with ROP and to evaluate the changes in serum VEGF concentrations after intravitreal conbercept (IVC). Sixty infants with ROP treated with IVC 0.25\u00a0mg were included. Blood samples were collected before treatment as well as 1\u00a0week and 4\u00a0weeks after treatment. Serum levels of 45 types of cytokines were measured by a multiplex bead assay. We observed that IVC 0.25\u00a0mg in ROP patients suppressed the circulating levels of VEGF-A and VEGF-D as of 1\u00a0week after injection, and these growth factor levels returned to baseline at 4\u00a0weeks. No significant differences were observed in the serum levels of the other cytokines between baseline and 1 or 4\u00a0weeks after IVC.<\/jats:p>","DOI":"10.1038\/s41598-020-69684-7","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T06:04:12Z","timestamp":1596002652000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Serum levels of cytokines in infants treated with conbercept for retinopathy of prematurity"],"prefix":"10.1038","volume":"10","author":[{"given":"Yong","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuemei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Linghu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongsheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,29]]},"reference":[{"key":"69684_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","volume":"84","author":"C Gilbert","year":"2008","unstructured":"Gilbert, C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum. Dev. 84, 77\u201382. https:\/\/doi.org\/10.1016\/j.earlhumdev.2007.11.009 (2008).","journal-title":"Early Hum. Dev."},{"key":"69684_CR2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","volume":"125","author":"D Lepore","year":"2018","unstructured":"Lepore, D. et al. Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology 125, 218\u2013226. https:\/\/doi.org\/10.1016\/j.ophtha.2017.08.005 (2018).","journal-title":"Ophthalmology"},{"key":"69684_CR3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","volume":"153","author":"T Sato","year":"2012","unstructured":"Sato, T. et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am. J. Ophthalmo. 153, 327\u2013333. https:\/\/doi.org\/10.1016\/j.ajo.2011.07.005 (2012).","journal-title":"Am. J. Ophthalmo."},{"key":"69684_CR4","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1111\/j.1755-3768.2012.02469.x","volume":"91","author":"R Hoerster","year":"2013","unstructured":"Hoerster, R. et al. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol. 91, e74-75. https:\/\/doi.org\/10.1111\/j.1755-3768.2012.02469.x (2013).","journal-title":"Acta Ophthalmol."},{"key":"69684_CR5","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","volume":"37","author":"WC Wu","year":"2017","unstructured":"Wu, W. C. et al. Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina 37, 694\u2013701. https:\/\/doi.org\/10.1097\/IAE.0000000000001209 (2017).","journal-title":"Retina"},{"key":"69684_CR6","doi-asserted-by":"publisher","first-page":"10732","DOI":"10.1038\/s41598-018-28987-6","volume":"8","author":"Y Cheng","year":"2018","unstructured":"Cheng, Y., Meng, Q., Linghu, D., Zhao, M. & Liang, J. A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity. Sci. Rep. 8, 10732. https:\/\/doi.org\/10.1038\/s41598-018-28987-6 (2018).","journal-title":"Sci. Rep."},{"key":"69684_CR7","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1097\/IAE.0000000000001763","volume":"38","author":"E Jin","year":"2018","unstructured":"Jin, E., Yin, H., Li, X. & Zhao, M. Short-term outcomes after intravitreal injections of conbercept versus ranibizumab for the treatment of retinopathy of prematurity. Retina 38, 1595\u20131604. https:\/\/doi.org\/10.1097\/IAE.0000000000001763 (2018).","journal-title":"Retina"},{"key":"69684_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2017-311662","author":"Y Bai","year":"2018","unstructured":"Bai, Y. et al. Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity. Br. J. Ophthalmol.  https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311662 (2018).","journal-title":"Br. J. Ophthalmol."},{"key":"69684_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.siny.2011.08.007","volume":"17","author":"J Lee","year":"2012","unstructured":"Lee, J. & Dammann, O. Perinatal infection, inflammation, and retinopathy of prematurity. Semin. Fetal neonatal Med. 17, 26\u201329. https:\/\/doi.org\/10.1016\/j.siny.2011.08.007 (2012).","journal-title":"Semin. Fetal neonatal Med."},{"key":"69684_CR10","doi-asserted-by":"publisher","first-page":"e736","DOI":"10.1542\/peds.2009-2017","volume":"125","author":"G Klinger","year":"2010","unstructured":"Klinger, G. et al. Outcome of early-onset sepsis in a national cohort of very low birth weight infants. Pediatrics 125, e736-740. https:\/\/doi.org\/10.1542\/peds.2009-2017 (2010).","journal-title":"Pediatrics"},{"key":"69684_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1742-2094-11-87","volume":"11","author":"HK Hong","year":"2014","unstructured":"Hong, H. K. et al. Neonatal systemic inflammation in rats alters retinal vessel development and simulates pathologic features of retinopathy of prematurity. J. Neuroinflamm. 11, 87. https:\/\/doi.org\/10.1186\/1742-2094-11-87 (2014).","journal-title":"J. Neuroinflamm."},{"key":"69684_CR12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1203\/PDR.0b013e3181d01a36","volume":"67","author":"BG Sood","year":"2010","unstructured":"Sood, B. G. et al. Perinatal systemic inflammatory response syndrome and retinopathy of prematurity. Pediatr. Res. 67, 394\u2013400. https:\/\/doi.org\/10.1203\/PDR.0b013e3181d01a36 (2010).","journal-title":"Pediatr. Res."},{"key":"69684_CR13","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1111\/apm.12223","volume":"122","author":"H Yu","year":"2014","unstructured":"Yu, H. et al. Serum concentrations of cytokines in infants with retinopathy of prematurity. APMIS 122, 818\u2013823. https:\/\/doi.org\/10.1111\/apm.12223 (2014).","journal-title":"APMIS"},{"key":"69684_CR14","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1167\/iovs.10-6279","volume":"52","author":"RC Silveira","year":"2011","unstructured":"Silveira, R. C., Fortes Filho, J. B. & Procianoy, R. S. Assessment of the contribution of cytokine plasma levels to detect retinopathy of prematurity in very low birth weight infants. Investig. Ophthalmol. Vis. Sci. 52, 1297\u20131301. https:\/\/doi.org\/10.1167\/iovs.10-6279 (2011).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"69684_CR15","doi-asserted-by":"publisher","first-page":"6419","DOI":"10.1167\/iovs.17-21931","volume":"58","author":"M Holm","year":"2017","unstructured":"Holm, M. et al. Systemic inflammation-associated proteins and retinopathy of prematurity in infants born before the 28th week of gestation. Invest. Ophthalmol. Vis. Sci. 58, 6419\u20136428. https:\/\/doi.org\/10.1167\/iovs.17-21931 (2017).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"69684_CR16","doi-asserted-by":"publisher","unstructured":"16International Committee for the Classification of Retinopathy of, P. The International Classification of Retinopathy of Prematurity revisited. Arch. Ophthalmol. 123, 991\u2013999, https:\/\/doi.org\/10.1001\/archopht.123.7.991 (2005).","DOI":"10.1001\/archopht.123.7.991"},{"key":"69684_CR17","doi-asserted-by":"publisher","first-page":"e0177337","DOI":"10.1371\/journal.pone.0177337","volume":"12","author":"Y Cheng","year":"2017","unstructured":"Cheng, Y. et al. Analysis of aqueous humor concentrations of cytokines in retinoblastoma. PLoS ONE 12, e0177337. https:\/\/doi.org\/10.1371\/journal.pone.0177337 (2017).","journal-title":"PLoS ONE"},{"key":"69684_CR18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","volume":"133","author":"WC Wu","year":"2015","unstructured":"Wu, W. C. et al. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol. 133, 391\u2013397. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.5373 (2015).","journal-title":"JAMA Ophthalmol."},{"key":"69684_CR19","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1097\/IAE.0000000000000535","volume":"35","author":"YR Hong","year":"2015","unstructured":"Hong, Y. R. et al. Plasma concentrations of vascular endothelial growth factor in retinopathy of prematurity after intravitreal bevacizumab injection. Retina 35, 1772\u20131777. https:\/\/doi.org\/10.1097\/IAE.0000000000000535 (2015).","journal-title":"Retina"},{"key":"69684_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00417-015-2996-0","volume":"254","author":"Y Zhou","year":"2016","unstructured":"Zhou, Y., Jiang, Y., Bai, Y., Wen, J. & Chen, L. Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab. Graefe\u2019s Arch. Clin. Exp. Ophthalmol. 254, 31\u201336. https:\/\/doi.org\/10.1007\/s00417-015-2996-0 (2016).","journal-title":"Graefe's Arch. Clin. Exp. Ophthalmol."},{"key":"69684_CR21","doi-asserted-by":"publisher","first-page":"2985161","DOI":"10.1155\/2019\/2985161","volume":"2019","author":"X Chen","year":"2019","unstructured":"Chen, X. et al. Serum vascular endothelial growth factor levels before and after intravitreous ranibizumab injection for retinopathy of prematurity. J. Ophthalmol. 2019, 2985161. https:\/\/doi.org\/10.1155\/2019\/2985161 (2019).","journal-title":"J. Ophthalmol."},{"key":"69684_CR22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","volume":"256","author":"CY Huang","year":"2018","unstructured":"Huang, C. Y. et al. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity. Graefe\u2019s Arch. Clin. Exp. Ophthalmol. 256, 479\u2013487. https:\/\/doi.org\/10.1007\/s00417-017-3878-4 (2018).","journal-title":"Graefe's Arch. Clin. Exp. Ophthalmol."},{"key":"69684_CR23","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.2147\/DDDT.S67536","volume":"9","author":"X Lu","year":"2015","unstructured":"Lu, X. & Sun, X. Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug design, Dev. Therapy 9, 2311\u20132320. https:\/\/doi.org\/10.2147\/DDDT.S67536 (2015).","journal-title":"Drug design, Dev. Therapy"},{"key":"69684_CR24","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s41433-018-0021-7","volume":"32","author":"S Fogli","year":"2018","unstructured":"Fogli, S. et al. Clinical pharmacology of intravitreal anti-VEGF drugs. Eye 32, 1010\u20131020. https:\/\/doi.org\/10.1038\/s41433-018-0021-7 (2018).","journal-title":"Eye"},{"key":"69684_CR25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.exer.2011.09.002","volume":"97","author":"H Li","year":"2012","unstructured":"Li, H. et al. Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit. Exp. Eye Res. 97, 154\u2013159. https:\/\/doi.org\/10.1016\/j.exer.2011.09.002 (2012).","journal-title":"Exp. Eye Res."},{"key":"69684_CR26","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/bjo.2007.134874","volume":"92","author":"MW Stewart","year":"2008","unstructured":"Stewart, M. W. & Rosenfeld, P. J. Predicted biological activity of intravitreal VEGF Trap. Br. J. Ophthalmol. 92, 667\u2013668. https:\/\/doi.org\/10.1136\/bjo.2007.134874 (2008).","journal-title":"Br. J. Ophthalmol."},{"key":"69684_CR27","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2147\/OPTH.S19555","volume":"5","author":"CI Sinapis","year":"2011","unstructured":"Sinapis, C. I. et al. Pharmacokinetics of intravitreal bevacizumab (Avastin(R)) in rabbits. Clin. Ophthalmol. 5, 697\u2013704. https:\/\/doi.org\/10.2147\/OPTH.S19555 (2011).","journal-title":"Clin. Ophthalmol."},{"key":"69684_CR28","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ophtha.2010.08.008","volume":"118","author":"M Zhang","year":"2011","unstructured":"Zhang, M. et al. A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology 118, 672\u2013678. https:\/\/doi.org\/10.1016\/j.ophtha.2010.08.008 (2011).","journal-title":"Ophthalmology"},{"key":"69684_CR29","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1097\/IAE.0000000000001274","volume":"37","author":"E Jin","year":"2017","unstructured":"Jin, E. et al. Serum levels of vascular endothelial growth factor before and after intravitreal injection of ranibizumab or conbercept for neovascular age-related macular degeneration. Retina 37, 971\u2013977. https:\/\/doi.org\/10.1097\/IAE.0000000000001274 (2017).","journal-title":"Retina"},{"key":"69684_CR30","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s12519-014-0502-0","volume":"10","author":"AY Zhou","year":"2014","unstructured":"Zhou, A. Y. et al. Placental growth factor expression is reversed by antivascular endothelial growth factor therapy under hypoxic conditions. World J. Pediatr. 10, 262\u2013270. https:\/\/doi.org\/10.1007\/s12519-014-0502-0 (2014).","journal-title":"World J. Pediatr."},{"key":"69684_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ijgo.2003.08.009","volume":"85","author":"G Galazios","year":"2004","unstructured":"Galazios, G. et al. Umbilical cord serum vascular endothelial growth factor (VEGF) levels in normal pregnancies and in pregnancies complicated by preterm delivery or pre-eclampsia. Int. J. Gynaecol. Obstet. Off. Organ Int. Federation Gynaecol. Obstet. 85, 6\u201311. https:\/\/doi.org\/10.1016\/j.ijgo.2003.08.009 (2004).","journal-title":"Int. J. Gynaecol. Obstet. Off. Organ Int. Federation Gynaecol. Obstet."},{"key":"69684_CR32","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1167\/iovs.13-11837","volume":"54","author":"SJ Woo","year":"2013","unstructured":"Woo, S. J. et al. The relationship between cord blood cytokine levels and perinatal factors and retinopathy of prematurity: a gestational age-matched case-control study. Investig. Ophthalmol. Vis. Sci. 54, 3434\u20133439. https:\/\/doi.org\/10.1167\/iovs.13-11837 (2013).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"69684_CR33","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1136\/bjo.2007.128371","volume":"92","author":"C Pieh","year":"2008","unstructured":"Pieh, C. et al. VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity. Br. J. Ophthalmol. 92, 689\u2013693. https:\/\/doi.org\/10.1136\/bjo.2007.128371 (2008).","journal-title":"Br. J. Ophthalmol."},{"key":"69684_CR34","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.4103\/0366-6999.164937","volume":"128","author":"M Zhao","year":"2015","unstructured":"Zhao, M. et al. Expression of total vascular endothelial growth factor and the anti-angiogenic VEGF 165 b isoform in the vitreous of patients with retinopathy of prematurity. Chin. Med. J. 128, 2505\u20132509. https:\/\/doi.org\/10.4103\/0366-6999.164937 (2015).","journal-title":"Chin. Med. J."},{"key":"69684_CR35","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2147\/OPTH.S11650","volume":"4","author":"R Velez-Montoya","year":"2010","unstructured":"Velez-Montoya, R. et al. Intraocular and systemic levels of vascular endothelial growth factor in advanced cases of retinopathy of prematurity. Clin. Ophthalmol. 4, 947\u2013953 (2010).","journal-title":"Clin. Ophthalmol."},{"key":"69684_CR36","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1203\/00006450-200205000-00018","volume":"51","author":"SE Sullivan","year":"2002","unstructured":"Sullivan, S. E. et al. Circulating concentrations of chemokines in cord blood, neonates, and adults. Pediatr. Res. 51, 653\u2013657. https:\/\/doi.org\/10.1203\/00006450-200205000-00018 (2002).","journal-title":"Pediatr. Res."},{"key":"69684_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/glia.10079","volume":"39","author":"Y Luo","year":"2002","unstructured":"Luo, Y. et al. RANTES stimulates inflammatory cascades and receptor modulation in murine astrocytes. Glia 39, 19\u201330. https:\/\/doi.org\/10.1002\/glia.10079 (2002).","journal-title":"Glia"},{"key":"69684_CR38","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00018-013-1459-1","volume":"71","author":"Y Yao","year":"2014","unstructured":"Yao, Y. & Tsirka, S. E. Monocyte chemoattractant protein-1 and the blood-brain barrier. Cell. Mol. Life Sci. CMLS 71, 683\u2013697. https:\/\/doi.org\/10.1007\/s00018-013-1459-1 (2014).","journal-title":"Cell. Mol. Life Sci. CMLS"},{"key":"69684_CR39","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/j.ophtha.2009.04.026","volume":"116","author":"T Sato","year":"2009","unstructured":"Sato, T., Kusaka, S., Shimojo, H. & Fujikado, T. Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. Ophthalmology 116, 2165\u20132169. https:\/\/doi.org\/10.1016\/j.ophtha.2009.04.026 (2009).","journal-title":"Ophthalmology"},{"key":"69684_CR40","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s00417-018-4034-5","volume":"256","author":"J Lyu","year":"2018","unstructured":"Lyu, J. et al. Aqueous cytokine levels associated with severity of type 1 retinopathy of prematurity and treatment response to ranibizumab. Graefe\u2019s Arch. Clin. Exp. Ophthalmol. 256, 1469\u20131477. https:\/\/doi.org\/10.1007\/s00417-018-4034-5 (2018).","journal-title":"Graefe's Arch. Clin. Exp. Ophthalmol."},{"key":"69684_CR41","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.ajpath.2013.05.017","volume":"183","author":"M Sugimoto","year":"2013","unstructured":"Sugimoto, M. et al. Inhibition of EGF signaling protects the diabetic retina from insulin-induced vascular leakage. Am. J. Pathol. 183, 987\u2013995. https:\/\/doi.org\/10.1016\/j.ajpath.2013.05.017 (2013).","journal-title":"Am. J. Pathol."},{"key":"69684_CR42","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0006-291X(02)00677-0","volume":"295","author":"A Luttun","year":"2002","unstructured":"Luttun, A. et al. Loss of placental growth factor protects mice against vascular permeability in pathological conditions. Biochem. Biophys. Res. Commun. 295, 428\u2013434 (2002).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"69684_CR43","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/carcin\/bgn066","volume":"29","author":"ZB Han","year":"2008","unstructured":"Han, Z. B. et al. Hypoxia-inducible factor (HIF)-1 alpha directly enhances the transcriptional activity of stem cell factor (SCF) in response to hypoxia and epidermal growth factor (EGF). Carcinogenesis 29, 1853\u20131861. https:\/\/doi.org\/10.1093\/carcin\/bgn066 (2008).","journal-title":"Carcinogenesis"},{"key":"69684_CR44","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cytogfr.2016.11.005","volume":"34","author":"TB Garcia","year":"2017","unstructured":"Garcia, T. B., Hollborn, M. & Bringmann, A. Expression and signaling of NGF in the healthy and injured retina. Cytokine Growth Factor Rev. 34, 43\u201357. https:\/\/doi.org\/10.1016\/j.cytogfr.2016.11.005 (2017).","journal-title":"Cytokine Growth Factor Rev."},{"key":"69684_CR45","doi-asserted-by":"publisher","first-page":"5594","DOI":"10.1167\/iovs.17-21973","volume":"58","author":"JD Boss","year":"2017","unstructured":"Boss, J. D. et al. Assessment of neurotrophins and inflammatory mediators in vitreous of patients with diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 58, 5594\u20135603. https:\/\/doi.org\/10.1167\/iovs.17-21973 (2017).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"69684_CR46","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1167\/iovs.05-1046","volume":"47","author":"HD Modanlou","year":"2006","unstructured":"Modanlou, H. D. et al. Ontogeny of VEGF, IGF-I, and GH in neonatal rat serum, vitreous fluid, and retina from birth to weaning. Invest. Ophthalmol. Vis. Sci. 47, 738\u2013744. https:\/\/doi.org\/10.1167\/iovs.05-1046 (2006).","journal-title":"Invest. Ophthalmol. Vis. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69684-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69684-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69684-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T10:14:28Z","timestamp":1670321668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69684-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,29]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["69684"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-69684-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.17703\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.17703\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,29]]},"assertion":[{"value":"8 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12695"}}